William Blair analyst Myles Minter has reiterated their bullish stance on ALNY stock, giving a Buy rating on August 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter’s rating is based on Alnylam Pharma’s promising developments in their cardiovascular drug pipeline, particularly the progress of zilebesiran. Despite the KARDIA-3 trial not meeting its primary endpoint, the trial showed notable improvements in blood pressure and other cardiovascular markers, which are encouraging for future outcomes.
Alnylam’s strategic partnership with Roche/Genentech and the initiation of the Phase III ZENITH trial further bolster confidence in the company’s potential for success. The trial’s design, aiming for a significant relative risk reduction in cardiovascular outcomes, demonstrates a robust approach to addressing unmet medical needs. These factors collectively contribute to a positive outlook for Alnylam’s stock, justifying the Buy rating.
According to TipRanks, Minter is a 5-star analyst with an average return of 17.9% and a 57.68% success rate. Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Moderna, and Arcturus Therapeutics.